Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
05.10.2016
Vtesse Announces Dosing of First Patient in Germany for Phase 2b/3 Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease

Clinicians Continue to Enroll Children with NPC at Trial Sites in France, Spain, Turkey, the United States and the United Kingdom. 

Expansion to Australia Expected Soon

GAITHERSBURG, Md., Oct. 5, 2016 /PRNewswire/ -- Vtesse, Inc., a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, announced today that the first German patient has been dosed in its global, pivotal clinical trial of its investigational drug VTS-270 for Niemann-Pick Type C1 disease ("NPC"). VTS-270 is a well-characterized mixture of HPbCD with a specific compositional fingerprint that distinguishes it from other HPbCD mixtures. 

Dato
29.09.2016
scPharmaceuticals Announces Presentations on Subcutaneous Furosemide at HFSA Annual Meeting

Complete bioavailability and equivalent diuresis after subcutaneous administration under experimental conditions

Equivalent diuresis when compared to high dose IV in heart failure patients in need of treatment of fluid overload

LEXINGTON, Mass., September 19, 2016 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the presentation of results of two studies at the 20th Annual Heart Failure Society of America (HFSA) Scientific Meeting in Orlando, Florida.

Dato
19.09.2016
PsiOxus Therapeutics Announce Executive Team Reorganization with Two New C Level Appointments in the US

OXFORD, United Kingdom (BUSINESS WIRE) PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Dr Charles “Charlie” Morris as Chief Development Officer and Karen LaRochelle as Chief Business Officer, both of whom will be based in the United States. These are the first C Level appointments in the US for the Oxford, UK based company as part of a planned expansion both in the UK and the US.

Dato
09.09.2016
River Vision Announces Receipt of Breakthrough Designation from US FDA
NEW YORK, NY – September 6, 2016.  River Vision Development Corp. (RVDC) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for RV001 (teprotumumab) for the treatment of active moderate to severe Thyroid Eye Disease (TED), also called Graves’ Orbitopathy (GO). The designation is granted to products intended to treat a serious or life threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies.
Dato
05.09.2016
BONESUPPORT™‘s CERAMENT™|G Highly Effective Adjunct in the Single Stage Surgical Management of Chronic Osteomyelitis – Results from Prospective Study of 100 patients Published in The Bone and Joint Journal

Single stage surgical procedure achieves 96% infection eradication rate

Lund, Sweden, 1 September 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioresorbable bone graft substitute products to treat bone voids caused by trauma, infection, disease or related surgery, today announced the publication of a paper in The Bone and Joint Journal: Single-stage treatment of chronic osteomyelitis with a new absorbable gentamicin-loaded, calcium sulphate/hydroxyapatite biocomposite - A prospective series of 100 cases. McNally et al, The Bone and Joint Journal, 2016, Vol. 98-B, No. 9, p1289-96.

Dato
31.08.2016
BONESUPPORT™‘s CERAMENT™|G and CERAMENT™ V to be Featured Extensively at the 35th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) in Oxford, UK
Lund, Sweden, 30 August 2016 – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery, today announced that presentations and posters covering research with its CERAMENT G and CERAMENT V will feature extensively at the upcoming 35th Annual Meeting of the European Bone & Joint Infection Society (EBJIS) taking place September 1-3 in Oxford, UK – which is a key congress for physicians and surgeons managing patients with bone infections. CERAMENT G and CERAMENT V are the only CE-marked injectable antibiotic eluting bone graft substitutes which provide local sustained delivery of gentamicin and vancomycin, respectively.
Dato
16.08.2016
Acacia Pharma announces Positve Results From Pivotal Phase 3 Trial of BAREMSIS™ For The Treatment of PONV

AREMSIS now shown to treat PONV, as well as prevent it

Cambridge, UK – 12th August 2016: Acacia Pharma Group plc (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces positive results from a pivotal Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) for the treatment of established post-operative nausea & vomiting (“PONV”). These data further support the efficacy of BAREMSIS which has previously been shown to prevent PONV alone, and in combination with standard anti-emetics in pivotal Phase 3 prophylaxis studies.

Dato
10.08.2016
BONESUPPORT™ Receives FDA Approval to Initiate IDE Clinical Study with CERAMENT™G

FORTIFY Study to Assess CERAMENT G as part of Surgical Repair of Open

Diaphyseal Tibial Fractures

Lund, Sweden, 9 August – BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery, today announced that it has received approval from the US Food and Drug Administration (FDA) to begin an IDE (Investigational Device Exemption) study with CERAMENT G. CERAMENT G is an injectable antibiotic-eluting bone graft substitute that provides local sustained delivery of gentamicin. CERAMENT G received CE mark approval in February 2013 and is now marketed in 19 countries outside the US.

Dato
10.08.2016
Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment

August 09, 2016 09:00 AM Eastern Daylight Time

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, today announced the final closing of its Series C financing bringing an additional $10 million into the company and completing the Series C at $48.5 million. Proceeds from the financing will be used to advance development of Iconic’s lead molecule ICON-1 in retinal diseases as well begin clinical trials in ocular melanoma, Iconic’s first oncology indication. The final closing included new investor Xeraya Capital. Xeraya joins existing investors MPM Capital, HBM Healthcare Investments, H.I.G. BioHealth Partners, Lundbeckfonden Ventures, Cormorant Asset Management, and Osage University Partners in the Series C capital raise.

Dato
09.08.2016
Vtesse Secures Additional $17 Million in Series A Extension to Support Further Product Development and Expand the Ongoing Clinical Trial of VTS-270 for the Treatment of Niemann-Pick Type C1 Disease

Investment Supports Further Product/Technology Improvements and Expanded Access to the Company's Global, Pivotal Study

Clinicians Are Now Enrolling Patients at Sites in France, Spain and Turkey in Addition to US, UK and Germany

GAITHERSBURG, Md., July 25, 2016 /PRNewswire/ -- Vtesse, Inc., a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, announced today that it has secured $17 million in additional Series A funding in support of its global, pivotal clinical trial of VTS-270 for Niemann-Pick Type C1 disease ("NPC"). 

Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste